Clinical Trials Directory

Trials / Completed

CompletedNCT02672111

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
228 (actual)
Sponsor
Braeburn Pharmaceuticals · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Open-label multi-center, 48 week safety study, consistent with standard practice for long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly) and q4w (once monthly) and will have 3 phases: Screening, Treatment, and Follow-up.

Detailed description

Open-label multi-center, 48 week safety study, consistent with standard practice for long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly) and q4w (once monthly) and will have 3 phases: Screening, Treatment, and Follow-up. Patients who are currently taking sublingual (SL) BPN (weekly or monthly prescription visits) or individuals who are actively seeking BPN treatment but who have not yet begun a treatment regimen, may be eligible for the study. Following Screening, qualified subjects meeting inclusion criteria and not meeting exclusion criteria will be initiated on either CAM2038 q1w or q4w, based on their current treatment status (qualified subjects currently on SL BPN or seeking BPN treatment). Qualified subjects will be initiated or transitioned to CAM2038 q1w or q4w as follows: Initiation of BPN treatment - initiate with CAM2038 q1w Currently receiving SL BPN treatments - transfer to corresponding CAM2038 q1w or q4w dose

Conditions

Interventions

TypeNameDescription
DRUGCAM2038 q1w or q4w exposure to SL BPN/NX
DRUGCAM2038 q1w or q4w new to BPN treatment

Timeline

Start date
2015-11-01
Primary completion
2017-05-01
Completion
2017-05-01
First posted
2016-02-03
Last updated
2020-05-15
Results posted
2019-08-01

Locations

32 sites across 8 countries: United States, Australia, Denmark, Germany, Hungary, Sweden, Taiwan, United Kingdom

Source: ClinicalTrials.gov record NCT02672111. Inclusion in this directory is not an endorsement.